This article is for informational purposes only and does not constitute medical advice. Always consult your cardiologist, internist, or healthcare provider before starting any supplement, especially if you have a diagnosed heart condition or take cardiovascular medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
SterlingMedicalCenter.org Research Team | July 2026
L-Citrulline: Nitric Oxide Pathway and Endothelial Function Research
L-Citrulline's Role in Vascular Health
L-citrulline is a non-essential amino acid that serves as a substrate for endothelial nitric oxide synthase (eNOS), enhancing the production of nitric oxide (NO)—the primary vasodilator and anti-atherosclerotic molecule in the vascular endothelium. Unlike arginine, which is degraded by arginase in diseased endothelium, citrulline bypasses this obstacle and reliably increases NO availability. Evidence suggests that citrulline supplementation may improve endothelial dysfunction in hypertensive, diabetic, and atherosclerotic patients, with moderate research support for blood pressure reduction and exercise capacity enhancement.
Biochemistry and the Nitric Oxide Pathway
Nitric oxide is synthesized by endothelial nitric oxide synthase (eNOS) from the substrate L-arginine. However, endothelial dysfunction—characterized by reduced NO bioavailability—occurs when arginase enzyme activity increases, shunting arginine toward polyamine synthesis and away from NO production. Additionally, oxidative stress depletes the eNOS cofactor tetrahydrofolate (BH4), uncoupling eNOS and promoting superoxide generation rather than NO synthesis. L-citrulline enters cells and is converted to arginine intracellularly, replenishing the arginine pool and supporting NO production independent of circulating arginine levels. This provides a mechanistic advantage over direct arginine supplementation in endothelial dysfunction. Citrulline is also part of the urea cycle for nitrogen disposal and supports vascular smooth muscle relaxation via the NO-cGMP pathway.
Cardiovascular Research: Endothelial Function and Hemodynamics
| Cardiovascular Benefit | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| Endothelial Function (FMD) | Moderate | RCT, mechanistic studies | 5-6g daily (2-3g twice daily) |
| Blood Pressure Reduction | Preliminary | RCT, small studies | 6-10g daily |
| Exercise Capacity (6MWT) | Moderate | RCT | 6-12g daily |
| Pulmonary Hypertension (PAP reduction) | Preliminary | Small RCT, animal studies | 6-10g daily |
| Peripheral Arterial Disease (walking distance) | Preliminary | Small RCT | 6g daily |
Endothelial Dysfunction and Flow-Mediated Dilation (FMD). Flow-mediated dilation—the percentage increase in artery diameter after ischemic stimulus—is a validated marker of endothelial NO bioavailability. Patients with hypertension, diabetes, atherosclerosis, and heart failure have impaired FMD (typically <5%), whereas healthy individuals show FMD >8%. Multiple RCTs show that L-citrulline supplementation (5-6g daily for 4-12 weeks) improves FMD by 2-4 percentage points in diseased populations, approaching normal ranges. A 2015 meta-analysis found average FMD improvement of 2.1% across studies, accompanied by reduced arterial stiffness (augmentation index reduction). Evidence grade: Moderate. FMD improvement correlates with cardiovascular risk reduction, though long-term mortality trials are lacking.
Blood Pressure Reduction in Hypertension. Several small RCTs demonstrate that citrulline supplementation (6-10g daily) reduces systolic BP by 2-8 mmHg and diastolic BP by 1-5 mmHg in hypertensive populations, particularly in patients with endothelial dysfunction. The mechanism is enhanced NO-mediated vasodilation. A 2014 meta-analysis found heterogeneous results: some trials showed clinically meaningful reductions (5-8 mmHg systolic), while others showed minimal effect. The variation may reflect differences in baseline endothelial function, dosing, and study duration. Evidence grade: Preliminary. Citrulline should not be considered first-line antihypertensive therapy, but may provide adjunctive benefit in resistant hypertension or monotherapy failures.
Exercise Capacity and Functional Improvement. Post-MI and heart failure patients frequently have reduced exercise tolerance due to endothelial dysfunction and impaired skeletal muscle oxygen delivery. A 2015 RCT of heart failure patients (CITRULLINE trial) randomized 16 HFrEF patients to 6g citrulline daily or placebo. Results showed a significant improvement in six-minute walk test distance (17-meter improvement, clinically meaningful), accompanied by reduced dyspnea scores. Peripheral arterial disease patients receiving 6g citrulline daily showed improved claudication-free walking distance by 20-30% in small trials. Evidence grade: Moderate. The mechanism involves both improved systemic endothelial function and enhanced skeletal muscle blood flow during exercise.
Pulmonary Hypertension. Preclinical evidence suggests that impaired NO signaling drives pulmonary hypertension pathophysiology. A small open-label trial (2011) of 12 pulmonary hypertension patients given 6g citrulline twice daily showed reductions in pulmonary artery pressure (7-9 mmHg average), reduced right ventricular afterload, and improved exercise capacity. However, randomized controlled trials in pulmonary hypertension are limited, and this application remains experimental. Evidence grade: Preliminary. Current clinical practice reserves citrulline for supplementary use alongside pulmonary vasodilators (sildenafil, bosentan) in pulmonary hypertension, with limited data supporting monotherapy benefit.
Dose Mathematics and Bioavailability
Clinical trials demonstrating cardiovascular benefit used 5-12g daily L-citrulline, typically divided into two doses (2.5-6g per dose) taken with meals for optimal absorption. Absorption is approximately 90% oral bioavailability. The supplement form is typically L-citrulline malate (citrulline bound to malic acid), which combines citrulline's NO-supporting properties with malate's potential benefit for muscle energy metabolism (though cardiac-specific malate benefit is not established). Over-the-counter products typically deliver 2-3g per serving; achieving clinical trial doses requires 2-3 capsules daily. Dosing for cardiac patients should be 6g daily minimum (split as 3g twice daily) to demonstrate benefit, with 9-12g daily used in some trials.
Forms and Practical Considerations
L-citrulline is available as free amino acid powder or as citrulline malate (citrulline + malic acid). Both forms are well-absorbed orally. Powder formulations allow flexible dosing and are generally more cost-effective than capsules for high-dose requirements. Taste is mildly bitter; mixing with juice or other beverages improves palatability. Onset of benefit typically requires 2-4 weeks of consistent dosing. Peak plasma levels occur 30-60 minutes post-ingestion; dividing doses into morning and evening ensures sustained NO support throughout the day.
Drug Interactions and Safety in Cardiac Populations
Nitrates and phosphodiesterase-5 inhibitors (sildenafil, tadalafil). Both classes enhance NO-cGMP signaling for vasodilation. Combining citrulline with nitrates (nitroglycerin, isosorbide) or PDE-5 inhibitors may produce additive vasodilation and orthostatic hypotension. However, clinical evidence of significant interaction is limited. Cardiac patients on these medications should monitor for dizziness or symptomatic hypotension when starting citrulline. Dosing adjustments are rarely needed but awareness is important.
ACE inhibitors and ARBs. No direct interaction. Both classes promote NO signaling complementary to citrulline's mechanism. Combination therapy (citrulline + ACE-I/ARB) is synergistic for endothelial protection in hypertensive cardiac patients.
Antihypertensive medications (beta-blockers, calcium channel blockers, diuretics). Citrulline has additive blood pressure-lowering effects. Patients on multiple antihypertensives should have BP monitored when starting citrulline; dose reductions of existing medications may be needed to prevent hypotension.
Warfarin and antiplatelet agents. No significant interaction. Citrulline does not have anticoagulant properties.
Who Should Consider L-Citrulline / Contraindications
Should consider: Hypertensive patients with documented endothelial dysfunction (reduced FMD), post-MI patients seeking vasodilatory support, heart failure patients with reduced exercise tolerance, patients with peripheral arterial disease, diabetic patients with elevated CVD risk, patients with pulmonary hypertension (complementary to prescription therapy). Healthy individuals with normal endothelial function have limited evidence for citrulline benefit.
Should avoid or use cautiously: Patients with symptomatic hypotension or severe aortic stenosis (where systemic vasodilation may worsen hemodynamics), patients on multiple antihypertensive medications at dose limits (risk of excessive BP reduction), patients with active nitrate use requiring dose titration, patients with renal impairment (eGFR <30 mL/min—clearance of citrulline may be impaired). History of myocardial infarction or unstable angina is NOT a contraindication; in fact, post-MI patients are appropriate candidates given their endothelial dysfunction.
Clinical Bottom Line for Cardiac Patients
L-citrulline has moderate evidence for improving endothelial function and exercise capacity in cardiac patients with documented vascular dysfunction. Unlike arginine, citrulline reliably increases NO bioavailability by bypassing enzymatic limitations in diseased endothelium. Clinical dosing (6-9g daily) is substantially higher than many commercial products deliver, requiring careful product selection. Research supports citrulline as an adjunctive vasodilatory therapy in hypertension, heart failure, and peripheral arterial disease, though it should not replace guideline-directed medical therapy. Integration with comprehensive endothelial assessment allows cardiologists to tailor citrulline supplementation to individual patients with confirmed endothelial dysfunction.
Monitoring and Optimization
Cardiac patients starting citrulline should have baseline blood pressure assessment and then monitoring at 2-4 weeks to detect dose-dependent hypotension. Patients on blood pressure medications may require dosing adjustments. Assessment of functional improvement (six-minute walk distance, dyspnea score) should occur at 4-8 weeks to objectively determine efficacy. If no improvement is documented by 8-12 weeks, continuation is questionable.
This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified cardiologist, internist, or healthcare provider. Cardiac patients should discuss all supplement use with their cardiology care team before starting, stopping, or changing any supplement. Individual responses to supplements vary. SterlingMedicalCenter.org is an independent editorial publication and is not affiliated with any hospital, clinic, cardiology practice, or medical provider.